|
1
|
Weiss SW and Goldblum JR: General
considerations. Enzinger and Weiss’s Soft Tissue Tumors. Weiss SW
and Goldblum JR: 4th edition. Mosby Inc; St Louis, MO: pp. 1–19.
2001
|
|
2
|
Coindre JM, Terrier P, Guillou L, et al:
Predictive value of grade for metastasis development in the main
histologic types of adult soft tissue sarcomas: a study of 1240
patients from the French Federation of Cancer Centers Sarcoma
Group. Cancer. 91:1914–1926. 2001. View Article : Google Scholar
|
|
3
|
Frustaci S, Gherlinzoni F, De Paoli A, et
al: Adjuvant chemotherapy for adult soft tissue sarcomas of the
extremities and girdles: results of the Italian randomized
cooperative trial. J Clin Oncol. 19:1238–1247. 2001.PubMed/NCBI
|
|
4
|
Guillou L, Coindre JM, Bonichon F, et al:
Comparative study of the National Cancer Institute and French
Federation of Cancer Centers Sarcoma Group grading systems in a
population of 410 adult patients with soft tissue sarcoma. J Clin
Oncol. 15:350–362. 1997.
|
|
5
|
Oliveira AM and Nascimento AG: Grading in
soft tissue tumors: principles and problems. Skeletal Radiol.
30:543–559. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Troup S, Njue C, Kliewer EV, et al:
Reduced expression of the small leucine-rich proteoglycans,
lumican, and decorin is associated with poor outcome in
node-negative invasive breast cancer. Clin Cancer Res. 9:207–214.
2003.PubMed/NCBI
|
|
7
|
Matsumine A, Shintani K, Kusuzaki K, et
al: Expression of decorin, a small leucine-rich proteoglycan, as a
prognostic factor in soft tissue tumors. J Surg Oncol. 96:411–418.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shintani K, Matsumine A, Kusuzaki K, et
al: Expression of hypoxia-inducible factor (HIF)-1alpha as a
biomarker of outcome in soft-tissue sarcomas. Virchows Arch.
449:673–681. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nakamura T, Matsumine A, Matsubara T,
Asanuma K, Uchida A and Sudo A: Clinical significance of
pretreatment serum C-reactive protein level in soft tissue sarcoma.
Cancer. 118:1055–1061. 2012. View Article : Google Scholar
|
|
10
|
Nobis P, Zibirre R, Meyer G, Kühne J,
Warnecke G and Koch G: Production of a monoclonal antibody against
an epitope on HeLa cells that is the functional poliovirus binding
site. J Gen Virol. 66:2563–2569. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mendelsohn CL, Wimmer E and Racaniello VR:
Cellular receptor for poliovirus: molecular cloning, nucleotide
sequence, and expression of a new member of the immunoglobulin
super-family. Cell. 56:855–865. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takai Y, Irie K, Shimizu K, Sakisaka T and
Ikeda W: Nectins and nectin-like molecules: roles in cell adhesion,
migration, and polarization. Cancer Sci. 94:655–667. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takai Y, Miyoshi J, Ikeda W and Ogita H:
Nectins and nectin-like molecules: roles in contact inhibition of
cell movement and proliferation. Nat Rev Mol Cell Biol. 9:603–615.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Amano H, Ikeda W, Kawano S, et al:
Interaction and localization of Necl-5 and PDGF receptor beta at
the leading edges of moving NIH3T3 cells: Implications for
directional cell movement. Genes Cells. 13:269–284. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Irie K, Shimizu K, Sakisaka T, Ikeda W and
Takai Y: Roles and modes of action of nectins in cell-cell
adhesion. Semin Cell Dev Biol. 15:643–656. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ogita H and Takai Y: Nectins and
nectin-like molecules: roles in cell adhesion, polarization,
movement, and proliferation. IUBMB Life. 58:334–343. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Masson D, Jarry A, Baury B, et al:
Overexpression of CD155 gene in human colorectal carcinoma. Gut.
49:236–240. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Solecki D, Wimmer E, Lipp M and Bernhardt
G: Identification and characterization of the cis-acting elements
of the human CD155 gene core promoter. J Biol Chem. 274:1791–1800.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Solecki D, Bernhardt G, Lipp M and Wimmer
E: Identification of a nuclear respiratory factor-1 binding site
within the core promoter of the human polio virus receptor/CD155
gene. J Biol Chem. 275:12453–12462. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sloan KE, Eustace BK, Stewart JK, et al:
CD155/PVR plays a key role in cell motility during tumor cell
invasion and migration. BMC Cancer. 4:732004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ikeda W, Kakunaga S, Takekuni K, et al:
Nectin-like molecule-5/Tage4 enhances cell migration in an
integrin-dependent, nectin-3-independent manner. J Biol Chem.
279:18015–18025. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kakunaga S, Ikeda W, Shingai T, et al:
Enhancement of serum- and platelet-derived growth factor-induced
cell proliferation by Necl-5/Tage4/poliovirus receptor/CD155
through the Ras-Raf-MEK-ERK signaling. J Biol Chem.
279:36419–36425. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ikeda W, Kakunaga S, Itoh S, et al:
Tage4/Nectin-like molecule-5 heterophilically trans-interacts with
cell adhesion molecule Nectin-3 and enhances cell migration. J Biol
Chem. 278:28167–28172. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abe A, Fukui H, Fujii S, et al: Role of
Necl-5 in the pathophysiology of colorectal lesions induced by
dimethylhydrazine and/or dextran sodium sulphate. J Pathol.
217:42–53. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nakai R, Maniwa Y, Tanaka Y, et al:
Overexpression of Necl-5 correlates with unfavorable prognosis in
patients with lung adenocarcinoma. Cancer Sci. 101:1326–1330. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Atsumi S, Matsumine A, Toyoda H, et al:
Oncolytic virotherapy for human bone and soft tissue sarcomas using
live-attenuated poliovirus. Int J Oncol. 41:893–902.
2012.PubMed/NCBI
|
|
27
|
Enloe BM and Jay DG: Inhibition of Necl-5
(CD155/PVR) reduces glioblastoma dispersal and decreases MMP-2
expression and activity. J Neurooncol. 102:225–235. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Merrill MK, Bernhardt G, Sampson JH,
Wikstrand CJ, Bigner DD and Gromeier M: Polovirus receptor
CD155-targeted oncolysis of glioma. Neuro Oncol. 6:208–217. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Toyoda H, Ido M, Hayashi T, Gabbazza EC,
et al: Experimental treatment of human neuroblastoma using
live-attenuated poliovirus. Int J Oncol. 24:49–58. 2004.PubMed/NCBI
|
|
30
|
Minami Y, Ikeda W, Kajita M, et al:
Necl-5/poliovirus receptor interacts in cis with integrin
alphaVbeta3 and regulates its clustering and focal complex
formation. J Biol Chem. 282:18481–18496. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tonn JC, Kerkau S, Hanke A, et al: Effect
of synthetic matrix-metalloproteinase inhibitors on invasive
capacity and proliferation of human malignant gliomas in vitro. Int
J Cancer. 80:764–772. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ren RB, Costantini F, Gorgacz EJ, Lee JJ
and Racaniello VR: Transgenic mice expressing a human poliovirus
receptor: a newmodel for poliomyelitis. Cell. 63:353–362. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Koike S, Taya C, Kurata T, et al:
Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci USA.
88:951–955. 1991. View Article : Google Scholar
|
